Virios therapeutics announces plans to advance lead candidate imc-1 to phase 3 development as a new treatment option for fibromyalgia

Atlanta, aug. 09, 2023 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“fm”) and long-covid, today announced that the food & drug administration (“fda”) communicated that, following their initial review of the company's chronic toxicology program, the program's studies appear adequate to support the safety of imc-1 at the dose proposed by the company for chronic use. with this critical feedback in hand, the company plans to initiate its proposed pharmacokinetic and food effect study (“pk”) this year, while concurrently resubmitting a final phase 3 program outline and study protocols for fda review. following completion of the pk study, the goal will be to begin enrollment in the first fibromyalgia phase 3 safety and efficacy study in mid-2024.
VIRI Ratings Summary
VIRI Quant Ranking